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Introduction
Niacin, either alone or in combination with a sta-
tin, safely and effectively addresses most lipid
abnormalities in patients with mixed dyslipidaemia.
Therapeutically used for more than 50 years, niacin
is the most effective clinically available agent for
increasing high-density lipoprotein cholesterol
(HDL-C) levels. In most patients, niacin increases
HDL-C by 20–40% (1–5). Niacin also has beneﬁcial
effects on all known pro-atherogenic lipid parame-
ters, including lowering low-density lipoprotein
cholesterol (LDL-C), non-HDL-C and triglycerides.
It is the only current lipid therapy that decreases
Lp(a), an independent risk factor for atherosclerosis
(2,6). Niacin also has favourable effects on lipid
particle size; it reduces small, dense LDL (7) while
increasing cardio-protective HDL, as measured by
either particle size (HDL2) (8) or by apolipoprotein
proﬁle (HDL containing apolipoprotein A-I without
apolipoprotein A-II) (9). These alterations in lipids
are clinically meaningful, as treatment with niacin
has been associated with signiﬁcant reductions in
cardiovascular events and morbidity (10) and, in
combination with statins, with regression of athero-
sclerotic cardiovascular disease (11).
Despite niacin’s numerous beneﬁcial lipid effects,
patient compliance to long-term therapy is chal-
lenged by ﬂushing, a common side effect of niacin. A
signiﬁcant portion of the effects of niacin on ﬂushing
results from activation of the niacin receptor G pro-
tein-coupled receptor 109A (GPR109A) in dermal
Langerhans cells (12,13), leading to the production
of prostaglandins, including prostaglandin D2
(PGD2) and prostaglandin E2 (PGE2), which act on
receptors in the capillaries. Flushing is characterised
by cutaneous vasodilatation and manifests itself as
redness or warmth of the skin, sometimes accompa-
nied by tingling or itching. The onset of ﬂushing can
occur rapidly and usually lasts about 1 h. It is a tran-
sient, non-allergic response, but it may result in
patient discomfort. In a randomised dose escalation
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Aims: To summarise the metabolic responses to niacin that can lead to ﬂushing
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Niacin induces ﬂushing through dermal Langerhans cells where the activation of G
protein-coupled receptor 109A (GPR109A) increases arachidonic acid and prosta-
glandins, such as prostaglandin D2 (PGD2) and prostaglandin E2 (PGE2), subse-
quently activating prostaglandin D2 receptor (DP1), prostaglandin E2 receptor (EP2)
and prostaglandin E receptor 4 (EP4) in capillaries and causing cutaneous vasodila-
tation. Controlling niacin absorption rates, inhibiting prostaglandin production, or
blocking DP1,E P 2 and EP4 receptors can inhibit ﬂushing. Niacin extended-release
(NER) formulations have reduced ﬂushing incidence, duration and severity relative
to crystalline immediate-release niacin with similar lipid efﬁcacy. Non-steroidal
anti-inﬂammatory drugs (NSAIDs), notably aspirin given 30 min before NER at
bedtime, further reduce ﬂushing. An antagonist to the DP1 receptor (laropiprant)
combined with an ER niacin formulation can reduce ﬂushing; however, signiﬁcant
residual ﬂushing occurs with clinically-relevant dosages. Conclusions: Niacin is an
attractive option for treating dyslipidemic patients, and tolerance to niacin-induced
ﬂushing develops rapidly. Healthcare professionals should particularly address
ﬂushing during niacin dose titration.
Review Criteria
Research regarding the mechanism of action of
niacin and the formulations and agents used in the
mitigation of ﬂushing were systematically reviewed
and summarised. PubMed was searched from 1960
to 2008 using the terms niacin, ﬂushing,
laropiprant, prostaglandins and aspirin. All hits
were reviewed for inclusion of mechanism of
action, and pertinent articles were included,
excluding results which had been subsequently
disproven.
Message for the Clinic
Niacin, an attractive option for treating
dyslipidaemic patients, substantially improves most
lipid parameters associated with atherosclerosis.
However, ﬂushing is a common non-allergenic
response to niacin that reduces medication
compliance. Several options to mitigate ﬂushing
symptoms prior to the development of tolerance
are discussed. Clinical trials and practical
experience indicate that a high level of medication
compliance can be achieved if healthcare providers
counsel their patients prior to starting niacin
therapy.
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decreased from the highest (2.7 per patient per
month) with a 500-mg dose, and decreased to 1.1
with a 2000-mg dose (14). The incidence of ﬂushing
decreases with time as quickly as 1 week (15),
because tolerance develops via decreased prostanoid
(PGD2, a major mediator of ﬂushing) secretion with
repeated doses of niacin (15). This review summaris-
es the metabolic responses to niacin that can lead to
ﬂushing and examines the current strategies to man-
age the effects of ﬂushing in patients.
Niacin: mechanism of action
Physiologically, niacin inﬂuences lipoprotein metabo-
lism by decreasing triglyceride synthesis via multiple
pathways. In adipocytes, it inhibits the lipolysis of tri-
glycerides and retards the mobilisation of free fatty
acids (FFAs) to the plasma. As the liver uses plasma
FFAs as substrates to form triglycerides, hepatic tri-
glyceride production is decreased. Niacin can also
reduce de novo synthesis of triglycerides in the liver by
inhibiting the enzyme that catalyses the terminal reac-
tion in cellular triglyceride synthesis, diacylglycerol
acyltransferase 2 (DGAT2) (16). A reduction in hepa-
tic triglyceride synthesis has important downstream
effects on other lipoproteins. The production of very
low density lipoprotein (VLDL) particles and thus
VLDL-C is dependent on triglyceride synthesis in the
liver, and IDL-C and LDL-C are derived from VLDL-
C. Therefore, by decreasing hepatic triglyceride syn-
thesis, niacin impairs synthesis of VLDL and thus
decreases circulating levels of VLDL-C and subse-
quently IDL-C and LDL-C.
The mechanism through which niacin increases
HDL-C is under investigation. Niacin does not
appear to directly increase hepatic HDL particle or
apolipoprotein A-I (the most abundant lipoprotein
in HDL) synthesis. Instead, niacin likely prevents the
catabolism of circulating HDL through several ways.
Niacin decreases HDL catabolism by decreasing the
fractional clearance of ApoA-I associated with HDL
(17). When liver cells were treated with niacin, their
uptake of HDL was inhibited, but the uptake of its
cholesteryl ester was not (9). By preventing the hepa-
tic catabolism of HDL, but not the uptake of the
cholesteryl ester, niacin can increase the amount of
circulating functional HDL, and thus facilitate
reverse cholesterol transport. Therefore, the amount
of HDL-ApoA-I-containing lipoprotein particles
would be increased without increasing the rate of
production of these particles. Recent research indi-
cates that niacin decreases hepatocyte surface expres-
sion of beta-chain adenosine triphosphate (ATP)
synthase (18), a mitochondrial protein reported to
mediate hepatic HDL holoparticle endocytosis (19).
These ﬁndings suggest that niacin, by downregulating
hepatocyte surface expression of the beta-chain ATP
synthase, reduces hepatic removal of HDL through
holoparticle endocytosis, thus implicating a potential
cellular receptor site for niacin’s action to raise
plasma HDL.
Some of niacin’s effects on FFAs may be because
of its properties as a high-afﬁnity agonist for the
G-protein coupled receptor, GPR109A protein-upreg-
ulated in macrophages by interferon-c (PUMA-G) in
mice (20–22). In humans, GPR109A is expressed in
adipocytes, dermal immune cells (Langerhans) and
macrophages, but not in the liver (23). Mice that lack
the PUMA-G GPR109A receptor do not show
improvements in lipid parameters after niacin treat-
ment (21). Whether this mechanism operates in
humans is unclear because of rebound lipolysis that
occurs after the acute initial reduction (24). There is
strong evidence that activation of the GPR109A (12)
receptor in Langerhans cells (13) leads to ﬂushing,
even though the antilipolytic effects of niacin are
likely mediated through GPR109A receptors in the
adipocytes. Mice that lack the PUMA-G GPR109A
receptor do not ﬂush when administered niacin, but
can ﬂush after the receptor is restored in immune
cells following a bone marrow transplant from nor-
mal mice (12).
In addition to lipid effects, recent research also
suggested that niacin beneﬁcially affects vascular
inﬂammatory processes involved in atherogenesis.
The ﬁndings from these studies indicate for the ﬁrst
time that niacin inhibits vascular inﬂammation by
decreasing endothelial reactive oxygen species (ROS)
production resulting in decreased endothelial expres-
sion of redox-sensitive genes, vascular cell adhesion
molecule-1 (VCAM-1) and monocyte chemotactic
protein-1 (MCP-1), and monocyte⁄macrophage
adhesion and accumulation, key events in early ath-
erogenesis (25). These in vitro studies describe a
novel mechanistic role for niacin in decreasing ath-




Flushing symptoms occur following vasodilatation of
small capillaries under the skin, a response that can
be mediated via histamine⁄bradykinin or prostaglan-
dins. Flushing is not unique to niacin; it has also
been reported frequently by patients taking phospho-
diesterase inhibitors, selective serotonin reuptake
inhibitors (SSRIs), selective oestrogen receptor mod-
ulators (SERMs), adenosine and tretinoin. Topical
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ciated with increases in blood levels of either hista-
mine or bradykinin, suggesting that niacin-induced
ﬂushing is not mediated by mast cells (26,27). The
release of histamine or bradykinin causes a substan-
tial rise in nitric oxide, which leads to increased
intracellular release of cyclic guanosine monophos-
phate (cGMP) and vasodilatation. Elimination of
endothelial nitric oxide synthase (eNOS), an enzyme
critical for NO production, did not stop niacin-
induced ﬂushing in mice (12), providing further sup-
port that the histamine⁄bradykinin pathway is not
involved in niacin-induced ﬂushing.
Prostaglandins (PGs), speciﬁcally forms D2 and
E2, have been identiﬁed as participants in the
niacin-induced ﬂushing response (28,29). PGs, prosta-
cylcins, thromboxanes and leukotrienes, collectively
considered eicosanoids, are hormone-like chemical
messengers derived from arachidonic acid. PGs have
numerous biological effects, including essential roles
in platelet aggregation, neurotransmitter release, and
inﬂammatory and vasomotor responses. Individual
prostaglandins can have both positive and negative
effects (i.e. pro-inﬂammatory or anti-inﬂammatory,
vasodilatory or vasoconstrictive) depending upon
their concentration, relative proportion to other
prostaglandins and expression of receptor types. As
prostaglandins are rapidly metabolised and have short
half-lives, their metabolic effects are typically localised
and can be variable in different parts of the body.
The arachidonic acid cascade
Activation of the GPR109A receptor by niacin initi-
ates a signalling cascade that ultimately results in the
production of prostaglandins, and thus, ﬂushing
(Figure 1). In Langerhans cells, niacin can activate
GPR109A to increase intracellular Ca
2+ (13). This
Ca
2+ increase triggers phospholipases, predominantly
Phospholipase A2 (PLA2), to release arachidonic acid
from cellular lipid stores (30). Free arachidonic acid
serves as a precursor to the production of eicosa-
noids, including lipoxygenases, thromboxanes and
prostaglandins.
The production of prostaglandins from arachidonic
acid involves a complex cascade of enzymes. The ﬁrst
step is the metabolism of arachidonic acid to prosta-
glandin H2 (PGH2) by PGH synthase, an enzyme that
has both cyclooxygenase and endoperoxidase activity,
but is commonly referred to as COX. Sequential
metabolism of arachidonic acid by COX produces
prostaglandin G2 (PGG2), which is then reduced to
PGH2, an unstable intermediate. Aspirin and related
non-steroidal anti-inﬂammatory drugs (NSAIDs) can
prevent the synthesis of prostaglandins by inhibiting
both isoforms of COX (COX-1 and COX-2). The inhi-
bition of COX also eliminates the ﬂushing response to
niacin (28,31–33). From PGH2, multiple prostaglan-
din synthase enzymes synthesise PGD2, PGE2, prosta-
glandin I2 (PGI2, prostacyclin), thromboxane A2
(TXA2, thromboxane) and prostaglandin F2a (PGF2a).
Figure 1 Niacin activates the arachidonic acid cascade to induce vasodilatation. Niacin activates the G-protein coupled
receptor 109A (GPR109A) to increase cAMP and releases arachidonic acid from cell membranes. Arachidonic acid is
metabolised to produce prostaglandins, prostacyclin and thromboxane. Activation of the prostaglandin D2 receptor (DP1),
prostaglandin E2 receptor (EP2), EP4 and IP receptors can lead to vasodilatation that may contribute to ﬂushing. NSAIDs
block the metabolism of arachidonic acid, while LRP blocks DP1-mediated vasodilatation. cAMP, cyclic AMP; PLA2,
phospholipase A2; PG, Prostaglandin; CRTH2, chemoattractant receptor homologous-molecule expressed on T helper type
2; NA, nicotinic acid; NSAIDs, non-steroidal anti-inﬂammatory drugs; LRP, laropiprant
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effects locally through downstream receptors. There
are currently ﬁve known prostaglandin receptor fami-
lies activated by prostaglandins: DP, prostaglandin E
receptor (EP), prostacyclin receptor (IP), thrombox-
ane A2 receptor (TP) and F2a receptor (FP). The EP
receptors are further divided into four subtypes, pros-
taglandin E1 receptor (EP1), EP2,E P 3 and EP4, and
there are two DP receptor subtypes, DP1 and DP2,
also called chemoattractant receptor homologous-
molecule expressed on T helper type 2 (CRTH2). The
receptors are categorised by their afﬁnity for each
respective prostaglandin agonist. PGE2 binds to the
EP family, PGD2 binds to DP, PGI2 binds to IP and
so forth. The downstream effects of the activation of
each individual receptor can be dependent on the tis-
sue expression of the receptor as well as the G-protein
to which the receptor is coupled. These conditions
allow some of the receptors to have opposing actions
in the same tissue and result in complicated predic-
tions of receptor activation. Broadly, these receptors
can be divided into two groups, ‘relaxant’ or ‘excit-
atory’, according to their effects on smooth muscle.
The relaxant receptors consist of DP, EP2,E P 4 and
IP, whereas TP, EP1 and FP are categorised as excit-
atory (34). Based on this classiﬁcation, the relaxant
receptors would be expected to play a role in cutane-
ous vasodilatation, while the excitatory receptors
would act as vasoconstrictors.
Vasodilatory PGs
Through their downstream receptors, PGD2, PGE2
and PGI2 can all exhibit vasodilatory effects on
smooth muscle cells in the vasculature, among other
effects. Through the DP1 receptor, PGD2 inhibits
platelet aggregation and mediates smooth muscle
relaxation⁄contraction. Although PGD2 is known to
have vasodilatory properties in the vascular endothe-
lium, it can behave as a vasoconstrictor at higher
concentrations and in separate tissues (35). PGD2
can also act through the chemoattractant CRTH2
(DP2) receptor, whose biological role appears to be
regulating inﬂammatory allergic and asthmatic
responses (36). PGE2 is perhaps the most widely pro-
duced prostaglandin, and as the highest-afﬁnity ago-
nist for the EP receptor family, it exerts the most
diverse and versatile effects (37). The EP2 receptors
are localised to smooth muscle in the trachea, GI
tract and vascular system. They, along with EP4
receptors, are relaxant receptors and induce vasodila-
tation of various blood vessels through increasing
cAMP. The PGE2-EP4 receptor pathway may also
mediate some anti-inﬂammatory effects and facilitate
mobilisation, migration and maturation of Langer-
hans cells in the skin (38). Prostacyclin is the major
arachidonic acid product in vascular tissues (39).
PGI2 is produced in blood vessels where it is a
potent vasodilator and inhibitor of platelet aggrega-
tion through the IP receptor (34).
Vasoconstrictory PGs
Thromboxane and PGF2a, acting through the TP and
FP receptors, respectively, are both potent vasocon-
strictors. Thromboxane A2 (TXA2) plays an extensive
role in haemodynamics and cardiovascular function.
The majority of thromboxane produced in vivo is
made by platelets, where it exhibits opposing actions
to PGI2. TXA2 can increase platelet aggregation, and
thus deﬁciencies in the TP receptor can lead to
bleeding disorders. TP receptors are expressed in the
thymus, spleen and lungs. Increased TXA2 has been
linked to cardiovascular diseases including acute
myocardial ischaemia and heart failure (40). In
humans, PGF2a is a potent constrictor of pulmonary
arteries and veins (41,42). It increases blood pressure
in experimental animals, but not humans. As PGF2a
and TXA2 are potent vasoconstrictors, they are unli-
kely candidates to induce ﬂushing, but may blunt the
actions of vasodilatory prostaglandins.
Prostaglandins involved in ﬂushing
Several prostaglandins with vasodilatory properties
are inﬂuenced by niacin. Speciﬁcally, levels of PGD2,
PGE2, PGI2 and their metabolites have been shown
to be increased as quickly as 12–45 min after niacin
treatment (15,26,32,43). Their respective receptors,
DP, EP2 and EP4 and IP, can all induce relaxation of
blood vessels. After oral niacin treatment, PGD2 lev-
els in the venous blood draining the skin are
14–1200 times higher than the levels in arterial blood
(44). The production of PGI2 and PGD2 decreases
after repetitive administration of niacin in parallel
with the development of ﬂushing tolerance (15). Fur-
ther, methylnicotinate, which can deliver niacin
transdermally, applied to a subject’s arm releases
PGD2 only in the exposed arm, with no change in
the untreated arm (44). Langerhans cells express
PGD2 and PGE2 synthase enzymes (13), indicating
they can produce PGD2 and PGE2 to activate recep-
tors on blood vessels that lead to vasodilatation and
contribute to ﬂushing side effects. PUMA-G-deﬁcient
mice still ﬂush when administered PGD2 (12). Like-
wise, humans pretreated with the NSAID indometha-
cin still ﬂush when challenged with PGE (28).
Separate deletions of the DP1,E P 2 and EP4 in mice
result in 40%, 20% and 40% reductions in ﬂushing
response, respectively, relative to normal mice after
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of COX in mice completely eliminate ﬂushing after
niacin treatment (12). Mice that do not express the
IP receptor still ﬂush after niacin (12). These experi-
ments indicate that PGD2 and PGE2, signalling
through the DP1,E P 2 and EP4 receptors, are likely
responsible for the ﬂushing side effects of niacin.
Other products of arachidonic acid
Besides COX, arachidonic acid can be metabolised by
a family of enzymes called lipoxygenases to produce
leukotrienes (LT), a group of inﬂammatory lipid
mediators. They are released from neutrophils, eosin-
ophils, mast cells and macrophages to play a role in
innate immunity (45). Leukotrienes mediate asthma
effects, mucus secretion and bronchoconstric-
tion⁄bronchodilation. Leukotriene B4 (LTB4) applied
directly to the skin can cause vasodilatation that is not
decreased by COX inhibitors, indicating that the vaso-
dilatation is not mediated by prostaglandins (46). The
downstream mechanism of LTB4-mediated vasodilata-
tion is currently unknown. Patients treated with niacin
have shown evidence of increases in leukotriene E4
(LTE4) but not LTB4 (47). Any potential effects of
LTE4 on niacin-induced ﬂushing have not been
reported, and its role in vasodilatation is unclear.
Managing patient ﬂushing
Considering niacin’s beneﬁcial effects on nearly all
lipid parameters associated with cardiovascular risk,
and recent demonstration of its vascular anti-inﬂam-
matory properties (25), strategies to minimise or
eliminate ﬂushing should be deemed important to
increase patient compliance to niacin therapy. As
attenuation to ﬂushing rapidly develops (28), dose
titration is important in reducing ﬂushing in
patients. As a result of niacin’s mechanism of action,
ﬂushing can be managed in three ways: (i) by con-
trolling the absorption rate of niacin; (ii) by prevent-
ing the production of prostaglandins; or (iii) by
simultaneously blocking the DP1,E P 2 and EP4 recep-
tors. Educating patients about the beneﬁts of niacin
therapy may also increase the likelihood that patients
are willing to tolerate any of the minor bothersome
effects of ﬂushing (48).
New formulations of niacin
Flushing can persist as long as plasma niacin levels are
rising, but abates when constant plasma niacin levels
are reached (49). Therefore, ﬂushing is also related to
the rate of niacin absorption, as a higher rate of
absorption is associated with a higher rate of ﬂushing
(50,51). Crystalline, immediate-release (IR) niacin is
rapidly absorbed by the body, and peak blood levels
can be reached in as quickly as 30–60 min (52). As
such, ﬂushing incidence among patients taking IR nia-
cin is close to 100%, and ﬂushing was the major rea-
son for discontinuation of IR niacin in several studies
(53–55). To reduce ﬂushing, several alternate formula-
tions of niacin have been made. Sustained-release (SR)
niacin formulations were created to delay niacin
absorption during treatment. Although SR niacin
decreases ﬂushing, it can also cause hepatotoxicity and
has shown inconsistent effects on lipids (55,56). Inosi-
tol hexanicotinate is commonly referred to as no-ﬂush
niacin or ﬂush-free niacin, but this dietary supplement
has not been shown to have any beneﬁcial effects on
lipid parameters (57,58).
Newer prescription niacin extended-release (NER)
formulations (Niaspan
 , Abbott, Abbott Park, IL,
USA) have shown reduced ﬂushing side effects rela-
tive to IR niacin while having equivalent efﬁcacy to
alter lipid parameters (5). Among healthy subjects
receiving a single 2000 mg dose of a coated formula-
tion of NER, there was a 42% reduction in median
ﬂush intensity and a 43% reduction in median ﬂush
duration relative to an older formulation of NER
(59). In NER clinical trials, not more than 6% of
subjects discontinued because of ﬂushing (60). Flush-
ing side effects are less with 1000 mg than 2000 mg
of NER, and still retain roughly 70% of the improve-
ment in HDL-C. Once daily dosing of NER in a
59 week-study showed only two subjects out of 723
having aspartate aminotransferase (AST) levels > 3
times the upper limit of normal (ULN) and no sub-
jects with alanine aminotransferase (ALT) > 3 times
ULN (1). Trials involving the combination of NER
and a statin also show little evidence of hepatotoxic-
ity (61–63).
NER can be safely combined with statins to lower
LDL-C, triglycerides and non-HDL-C, while raising
HDL-C. This combination therapy does not appear to
worsen ﬂushing side effects, and NER has not been
shown to potentiate statin-induced myopathies. Com-
bination treatment with NER and simvastatin (NER⁄S,
SIMCOR
 , Abbott Laboratories) in recent clinical
trials showed this dual therapy was well tolerated
(64–66). In a randomised study, comparing combina-
tion NER⁄S to simvastatin alone (SEACOAST I), only
7.5% of subjects receiving 1000⁄20 mg⁄day or
2000⁄20 mg⁄day NER⁄S discontinued because of
ﬂushing (64). In a similar study (SEACOAST II), dis-
continuations caused by ﬂushing were not signiﬁcantly
different in subjects receiving NER⁄S 1000⁄40 mg⁄day
(4.3%) or 2000⁄40 mg⁄day (5.0%) relative to subjects
receiving simvastatin monotherapy and 50 mg⁄day of
IR niacin. In a long-term open-label study in subjects
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simvastatin, the discontinuation rate of subjects
receiving 2000⁄40 mg⁄day NER⁄S was only 7%
because of ﬂushing (66). As tolerance developed to
niacin alone, tolerance similarly developed to NER⁄S,
as > 60% of the subjects who ﬂushed during the ﬁrst
12-week titration phase did not ﬂush during weeks
41–52 (66).
Non-steroidal anti-inﬂammatory drugs
NSAIDs are convenient cotherapies with niacin to
reduce ﬂushing. They decrease the production of
multiple prostaglandins by preventing COX from
metabolising arachidonic acid. In a ﬂush-provocative
study, using healthy volunteers, aspirin given 30 min
before a 2000 mg dose of NER decreased the inci-
dence, duration and severity of ﬂushing compared
with placebo pretreatment (67). Among subjects
receiving placebo, 77% of subjects reported ﬂushing
with newer formulations of ER niacin. However, only
53% of subjects receiving aspirin 30 min before a
dose of a newer formulation of ER niacin ﬂushed
(67). Aspirin given concomitantly with NER was also
effective at reducing ﬂushing incidence, duration and
severity compared with placebo, but not as effective
as aspirin 30-min pretreatment (67). In a prospec-
tive, randomised, double-blind, placebo-controlled
trial, 325 mg aspirin given 30 min before a dose of
NER reduced both the number and intensity of
ﬂushing episodes, resulting in a lower rate of discon-
tinuation because of ﬂushing in the aspirin group
compared with placebo (1.8% vs. 9.4%; p = 0.007)
(68). Along with aspirin, indomethacin (33), ibupro-
fen (69) and naproxen (32) have been shown in sub-
jects to decrease the ﬂushing effects of IR niacin. The
most common dose of aspirin used to effectively
reduce ﬂushing in IR niacin is 325 mg, with 650 mg
offering no further beneﬁt (70). Aspirin use appears
to have no negative impact on niacin’s decrease of
free fatty acids (33).
DP1 receptor antagonists
Recent efforts to decrease the ﬂushing effects of nia-
cin have focused on eliminating the downstream
effects of prostaglandins that play a role in cutaneous
vasodilatation. A highly selective DP1 antagonist,
laropiprant [LRP, Merck⁄Merck Sharp & Dohm
(MSD)] is currently in clinical trials to be used con-
comitantly with an alternate formulation of
extended-release niacin from NER. In a small clinical
trial, using healthy volunteers, LRP administered
along with niacin decreased the symptoms of ﬂush-
ing compared with niacin plus placebo (71). How-
ever, about 70% of subjects taking a clinically
relevant dose (30 mg) of LRP along with 1500 mg of
niacin still ﬂushed (71). This high incidence is likely
caused by other pathways involved in the niacin
ﬂushing response. LRP is highly selective for DP1
and has no afﬁnity for inhibiting the EP2 or EP4
receptors (72), which are also highly likely involved
in ﬂushing (12). This situation underscores the difﬁ-
culty in modulating the downstream actions of pro-
staglandins for pharmacological effect.
GPR109 antagonists and other agents
Inhibiting the GPR109 receptor would theoretically
mitigate the ﬂushing response. Antagonism of the
GPR109 receptor to reduce ﬂushing while preserving
adipocyte antilipolytic activity would require target-
ing the Langerhans-speciﬁc GPR109A receptor. The
potential side effects are unknown. Another potential
target would be to inhibit the ability of PLA2 to
produce arachidonic acid, thereby eliminating the
production of prostaglandins upstream of COX.
Glucocorticoids can indirectly inhibit PLA2 (73,74),
but there are currently no approved therapies that
speciﬁcally target this enzyme.
Patient education
One of the easiest ways that medical personnel can
help improve their patients compliance with niacin
therapy is to provide their patients with a clear under-
standing of the clinical beneﬁts of niacin as well as
what to expect and how to manage ﬂushing (48).
While improvements in lipid proﬁles are meaningful
to physicians, patients may be more willing to tolerate
the transient ﬂushing symptoms that can occur if they
realise that niacin reduces cardiovascular risk, as
determined by both mortality and cardiovascular
event rates, and that this beneﬁt extends beyond the
duration of active therapy. Patients should be coun-
selled to take aspirin (325 mg) 30 min before a snack
and extended-release niacin. The importance of
continuing to take the ﬁnal daily maintenance dose of
niacin extended-release should be emphasised. If there
is a period of discontinuation, the titration procedure
has to be followed again, although it maybe possible to
accelerate it at the discretion of the prescriber. Patients
are also advised to avoid hot beverages, spicy foods
and hot showers near the time of taking niacin.
Conclusions
Given niacin’s beneﬁcial effects across a wide spec-
trum of the lipid proﬁle, proven safety record and
ability to be safely combined with statins, it should
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of dyslipidaemia. The same receptor that is responsi-
ble for niacin’s decrease in free fatty acids is also
likely the same receptor that is responsible for the
ﬂushing side effects. Therefore, it is currently difﬁcult
to separate the two effects, but ﬂushing can be effec-
tively managed in patients. As tolerance to ﬂushing
develops rapidly, healthcare professionals should par-
ticularly address ﬂushing during dose titration of
niacin. Clinically, unlike LRP, aspirin is not only an
established agent to reduce ﬂushing but it is also
indicated for use in most dyslipidemic patients to
reduce atherothrombotic complications, which is also
the reason to prescribe niacin. As COX is upstream
of PGD2, NSAIDs have the ability to block produc-
tion of PGD2, PGE2 and PGI2. LRP has only the abil-
ity to block PGD2-mediated ﬂushing. Initial data
indicate that aspirin or LRP combined with
extended-release niacin formulations have similar
impacts on niacin-induced ﬂushing in patients,
although it is difﬁcult to directly compare separate
clinical studies. A clinical trial to assess the relative
efﬁcacy of these two agents is needed. At least in
mice, deletion of the COX enzyme decreased ﬂushing
by almost 100%, while elimination of the DP1 recep-
tor only decreased ﬂushing by 40% after niacin treat-
ment. Aspirin has a well-known safety proﬁle, while
long-term data on the safety of LRP is awaited.
Future therapies that can preserve or even enhance
niacin’s important lipid effects while eliminating
ﬂushing will likely be important improvements in
the treatment of dyslipidaemia.
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